NOTICE 1 페이지

NEWS & EVENT

Total 12 - 1 page

No	Subject	Date	Hit
12	신주발행공고	2026.03.12	1,848
익명 1,848 2026.03.12
11	신주발행공고	2025.12.29	1,587
익명 1,587 2025.12.29
10	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	3,398
익명 3,398 2025.06.14
9	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	3,066
익명 3,066 2025.03.31
8	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	2,964
익명 2,964 2025.02.13
7	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	2,578
익명 2,578 2024.11.21
6	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	3,928
익명 3,928 2024.10.07
5	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	3,048
익명 3,048 2024.07.10
4	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	3,394
익명 3,394 2024.05.21
3	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	4,323
익명 4,323 2024.02.27
2	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	3,518
익명 3,518 2022.11.09
1	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	7,782
익명 7,782 2021.07.15

1페이지

INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT